CA3093340A1 - Kinase inhibitor compounds and compositions and methods of use - Google Patents
Kinase inhibitor compounds and compositions and methods of use Download PDFInfo
- Publication number
- CA3093340A1 CA3093340A1 CA3093340A CA3093340A CA3093340A1 CA 3093340 A1 CA3093340 A1 CA 3093340A1 CA 3093340 A CA3093340 A CA 3093340A CA 3093340 A CA3093340 A CA 3093340A CA 3093340 A1 CA3093340 A1 CA 3093340A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- compound
- compound according
- subject
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862645560P | 2018-03-20 | 2018-03-20 | |
| US62/645,560 | 2018-03-20 | ||
| PCT/US2019/023206 WO2019183245A1 (en) | 2018-03-20 | 2019-03-20 | Kinase inhibitor compounds and compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3093340A1 true CA3093340A1 (en) | 2019-09-26 |
Family
ID=67988050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3093340A Pending CA3093340A1 (en) | 2018-03-20 | 2019-03-20 | Kinase inhibitor compounds and compositions and methods of use |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11866427B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3768267B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2021518413A (cg-RX-API-DMAC10.html) |
| CN (1) | CN112135613A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019240065A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3093340A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES3038913T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019183245A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| JP2021510153A (ja) | 2018-01-05 | 2021-04-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 |
| ES3038913T3 (en) | 2018-03-20 | 2025-10-15 | Icahn School Med Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| CN115466312B (zh) * | 2021-06-10 | 2025-10-31 | 首都医科大学 | 抑制侵袭和迁移的1-咪唑-β-咔啉-3-甲酰-RGDV、其制备和应用 |
| CN114288291B (zh) * | 2021-12-28 | 2023-04-28 | 大连医科大学附属第一医院 | Norharman在制备预防或治疗急性胰腺炎药物中的应用 |
| CN114984195B (zh) * | 2022-04-29 | 2025-12-16 | 上海中医药大学 | 脂肪膜相关蛋白及其相关编码基因和片段的新用途 |
| CN114907346B (zh) * | 2022-05-19 | 2023-03-31 | 暨南大学 | 一种生物碱类化合物、提取物及其在制备具有抗呼吸道合胞病毒作用的产品中的应用 |
| CN115322089B (zh) * | 2022-07-18 | 2023-10-03 | 中国农业科学院烟草研究所(中国烟草总公司青州烟草研究所) | 一种覆盆子酮半抗原、人工抗原及其制备方法、抗体和应用 |
| WO2024178504A1 (en) * | 2023-02-27 | 2024-09-06 | Enveric Biosciences Canada Inc. | Tri-halo-alkoxy-substituted tryptamine derivatives and methods of using |
| US11802129B1 (en) | 2023-03-20 | 2023-10-31 | King Faisal University | Pyrido[3,4-b]indol-1-one compounds as anticancer agents |
| US11773092B1 (en) | 2023-03-27 | 2023-10-03 | King Faisal University | Pyrido[3,4-b]indol-1-one compounds as antibacterial agents |
| CN116509853B (zh) * | 2023-06-12 | 2025-01-28 | 新疆医科大学第一附属医院 | 去氢骆驼蓬碱衍生物在改善器官纤维化中的应用 |
| CN120916777A (zh) * | 2023-12-04 | 2025-11-07 | 珀维瓦公司 | 治疗糖尿病的组合物和方法 |
Family Cites Families (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2053549T3 (es) | 1986-08-11 | 1994-08-01 | Innovata Biomed Ltd | Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion. |
| US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
| GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| EP0460064A4 (en) | 1989-02-23 | 1992-04-01 | Rorer International (Holdings) Inc. | Therapeutic aerosol formulations |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| US5731144A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands |
| US5731424A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
| US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
| US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
| US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US5635161A (en) | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
| US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| ATE243998T1 (de) | 1995-10-12 | 2003-07-15 | Supergen Inc | Liposomformulierung von 5-beta steroiden |
| US6806358B1 (en) | 1997-12-16 | 2004-10-19 | University Of California San Diego | Peptide inhibitor of TGF-β growth factors |
| AU760046B2 (en) | 1998-02-27 | 2003-05-08 | United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs |
| GB9809869D0 (en) | 1998-05-09 | 1998-07-08 | Medical Res Council | Inhibition of protein kinases |
| JP2002535242A (ja) | 1998-05-20 | 2002-10-22 | ザ リポソーム カンパニー、インコーポレーテッド | 新規な粒子状剤型 |
| US6451349B1 (en) | 1998-08-19 | 2002-09-17 | Quadrant Healthcare (Uk) Limited | Spray-drying process for the preparation of microparticles |
| GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
| AUPP494798A0 (en) | 1998-07-29 | 1998-08-20 | Pacific Biolink Pty Limited | Protective protein formulation |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| US6290987B1 (en) | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| US6436367B1 (en) | 1998-12-21 | 2002-08-20 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
| EP1338272A1 (en) | 1998-12-21 | 2003-08-27 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate |
| US6294153B1 (en) | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| AU2879100A (en) | 1999-02-12 | 2000-08-29 | Miles A. Libbey Iii | Formulation and system for intra-oral delivery of pharmaceutical agents |
| AU3957400A (en) | 1999-04-16 | 2000-11-02 | Novo Nordisk A/S | Dry, mouldable drug formulation |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| AU5936400A (en) | 1999-06-04 | 2000-12-28 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| CA2382821A1 (en) | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| US20010036481A1 (en) | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| BR0107764A (pt) | 2000-01-20 | 2002-11-12 | Basilea Pharmaceutica Ag | Composições de peptìdeo cìclico nasalmente administráveis |
| EP1129705A1 (en) | 2000-02-17 | 2001-09-05 | Rijksuniversiteit te Groningen | Powder formulation for inhalation |
| JP2004500424A (ja) | 2000-04-17 | 2004-01-08 | ヴェクトゥラ リミテッド | 吸入器で使用するための製剤 |
| GB0009468D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| US20020155084A1 (en) | 2000-06-02 | 2002-10-24 | The Regents Of The University Of The Michigan | Nanoemulsion formulations |
| US6509318B1 (en) | 2000-09-29 | 2003-01-21 | The Regents Of The University Of California | TGF-B inhibitors and methods |
| FI20002768L (fi) | 2000-12-18 | 2002-06-19 | Licentia Oy | Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus |
| GB0107106D0 (en) | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations |
| SI1397364T1 (sl) | 2001-05-24 | 2007-12-31 | Lilly Co Eli | Novi pirolni derivati kot farmacevtske uäśinkovine |
| US20030019437A1 (en) | 2001-07-26 | 2003-01-30 | John Fore | Ungulate game animal feed system and method |
| US20030028905A1 (en) | 2001-07-31 | 2003-02-06 | Petra Knaus | Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms |
| US20030064033A1 (en) | 2001-08-16 | 2003-04-03 | Brown Larry R. | Propellant-based microparticle formulations |
| TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| WO2003072080A1 (en) | 2002-02-22 | 2003-09-04 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
| CA2478974C (en) | 2002-03-20 | 2014-12-16 | Advanced Inhalation Research, Inc. | Inhalable sustained therapeutic formulations |
| DE60307082D1 (de) | 2002-05-07 | 2006-09-07 | Ferring Bv | In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin |
| JP2005530800A (ja) | 2002-05-15 | 2005-10-13 | スミスクライン・ビーチャム・コーポレイション | ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール |
| AU2003229305A1 (en) | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
| US7190468B2 (en) | 2002-07-17 | 2007-03-13 | Hewlett-Packard Development Company, L.P. | Background document rendering system and method |
| EP1539748A1 (en) | 2002-07-31 | 2005-06-15 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| WO2004026871A1 (en) | 2002-09-17 | 2004-04-01 | Eli Lilly And Company | Novel pyrazolopyridine derivatves as pharmaceutical agents |
| JP2006502236A (ja) | 2002-09-18 | 2006-01-19 | ファイザー・プロダクツ・インク | 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体 |
| KR20050057441A (ko) | 2002-09-18 | 2005-06-16 | 화이자 프로덕츠 인코포레이티드 | 전환 성장 인자 억제제로서의 신규한 아이소티아졸 및아이속사졸 화합물 |
| WO2004026306A2 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| WO2004047818A2 (en) | 2002-11-22 | 2004-06-10 | Scios, Inc. | USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS |
| JP4896518B2 (ja) | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
| AU2003297460A1 (en) | 2002-12-19 | 2004-07-14 | Scios, Inc. | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS |
| JP2006516603A (ja) | 2003-01-27 | 2006-07-06 | ファイザー・プロダクツ・インク | イソチアゾール誘導体 |
| DE602004014347D1 (de) | 2003-03-12 | 2008-07-24 | Millennium Pharm Inc | Chinazolin-derivate als tgf-beta-inhibitoren |
| EP1608631A4 (en) | 2003-03-28 | 2008-08-20 | Scios Inc | BICYCLIC PYRIMIDININHIBITORS OF TGF BETA |
| ES2389258T3 (es) | 2003-06-17 | 2012-10-24 | Millennium Pharmaceuticals, Inc. | Composiciones y métodos para inhibir TGF-s |
| EP1644365A2 (en) | 2003-07-02 | 2006-04-12 | Biofocus Discovery Ltd | Pyrazine and pyridine derivatives as rho kinase inhibitors |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| JP4688680B2 (ja) | 2003-10-28 | 2011-05-25 | 独立行政法人理化学研究所 | TGF−β情報伝達経路阻害剤 |
| CA2551524A1 (en) | 2003-12-24 | 2005-07-21 | Scios, Inc. | Treatment of malignant gliomas with tgf-beta inhibitors |
| US7368445B2 (en) | 2004-03-01 | 2008-05-06 | Eli Lilly And Company | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms |
| US20090196912A1 (en) | 2004-07-30 | 2009-08-06 | Gpc Botech Ag | Pyridinylamines |
| JP2007176795A (ja) | 2004-08-18 | 2007-07-12 | Univ Nihon | TGF−β遺伝子発現抑制剤 |
| DK1789044T3 (da) | 2004-09-06 | 2010-12-06 | Basilea Pharmaceutica Ag | Phenylaminopyridiner og phenylaminopyraziner |
| HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| CN101189234B (zh) | 2005-03-25 | 2011-08-17 | 泰博特克药品有限公司 | Hcv的杂二环抑制剂 |
| CA2616196C (en) | 2005-07-22 | 2012-08-21 | Eli Lilly And Company | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
| AU2005337776B2 (en) | 2005-10-24 | 2013-01-31 | Proyecto De Biomedicina Cima, S.L. | Use of TGF-Beta1 inhibitor peptides in the preparation of an immune response modulating agent |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| ITMI20060181A1 (it) | 2006-02-03 | 2007-08-04 | Univ Padova | Modulatori del tgf-b e loro uso |
| BRPI0807961A2 (pt) | 2007-02-13 | 2017-05-16 | Pharmacopeia Llc | agonista de alfa2c adrenorreceptor funcionalmente seletivos. |
| GB0705566D0 (en) * | 2007-03-23 | 2007-05-02 | Univ Dundee | Method of treating learning impairment in down's syndrome subjects |
| EP2178537A4 (en) | 2007-07-19 | 2011-08-17 | Merck Sharp & Dohme | BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS |
| EP2197876A1 (en) | 2007-08-29 | 2010-06-23 | Glaxosmithkline LLC | Thiazole and oxazole kinase inhibitors |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| US8298825B1 (en) | 2008-08-25 | 2012-10-30 | The General Hospital Corporation | TGF-beta receptor inhibitors to enhance direct reprogramming |
| US20100173931A1 (en) | 2009-01-06 | 2010-07-08 | Osteogenex Inc. | Harmine derivatives for reducing body weight |
| WO2010123583A2 (en) | 2009-04-24 | 2010-10-28 | University Of Tennessee Research Foundation | 1-aryl or 1-heteroaryl-pyrido[b]indoles and uses thereof |
| AU2010247412A1 (en) | 2009-05-15 | 2011-11-24 | Novartis Ag | 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 |
| WO2010135589A2 (en) | 2009-05-20 | 2010-11-25 | Sakura Properties, Llc | Dietary supplement drink for delivery of resveratrol and other polyphenols |
| JP2011006408A (ja) | 2009-05-29 | 2011-01-13 | Sumitomo Chemical Co Ltd | 神経栄養因子の活性が関与する疾患の治療または予防剤 |
| CN102791134B (zh) | 2009-12-04 | 2015-04-22 | 魄金莱默有限公司 | 用多巴胺再摄取抑制剂及类似物治疗糖尿病症状和延迟或预防糖尿病相关病理学病况的方法 |
| WO2011075665A2 (en) | 2009-12-18 | 2011-06-23 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US20130102627A1 (en) | 2010-04-09 | 2013-04-25 | The Brigham And Women's Hospital, Inc. | Acridines As Inhibitors Of Haspin And DYRK Kinases |
| WO2011133795A2 (en) * | 2010-04-22 | 2011-10-27 | The Brigham And Women's Hospital, Inc. | Beta-carbolines as inhibitors of haspin and dyrk kinases |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| MX341025B (es) | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
| US9168247B2 (en) | 2010-06-25 | 2015-10-27 | Facultes Universitaires Notre Dame De La Paix | Beta carboline derivatives useful in the treatment of proliferative disorders |
| AU2011290123B2 (en) | 2010-08-09 | 2016-11-10 | Takeda Pharmaceutical Company Limited | Method of producing pancreatic hormone-producing cells |
| US20130165474A1 (en) * | 2010-08-17 | 2013-06-27 | Travis Dunckley | Compounds that inhibit tau phosphorylation |
| KR102006749B1 (ko) | 2011-08-19 | 2019-08-02 | 디악쏘니 | Dyrk1 억제제 및 이의 용도 |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| CN103070862A (zh) | 2011-10-25 | 2013-05-01 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物在制备抗菌药物中的应用 |
| WO2013119518A1 (en) | 2012-02-06 | 2013-08-15 | The Regents Of The University Of California | Small molecules for islet expansion |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| AU2013284460A1 (en) | 2012-06-27 | 2015-01-29 | Dmnomore | CTLA4 fusion proteins for the treatment of diabetes |
| WO2014018691A1 (en) | 2012-07-24 | 2014-01-30 | The Trustees Of Columbia University In The City Of New York | Generation of airway and lung progenitors and epithelial cells and three-dimensional anterior foregut spheres |
| CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
| JP2016500080A (ja) | 2012-11-26 | 2016-01-07 | 新疆華世丹薬物研究有限責任公司 | ビスβ−カルボリン系化合物、その製造方法、医薬組成物および用途 |
| JPWO2014058080A1 (ja) | 2012-11-30 | 2016-09-05 | 国立研究開発法人理化学研究所 | 体細胞のリプログラミングを亢進させる方法、及び細胞作製キット |
| CN102977096B (zh) * | 2012-12-07 | 2014-12-17 | 中国药科大学 | 具有靶向特性的去氢骆驼蓬碱衍生物的抗肿瘤前药 |
| MX2015007097A (es) | 2012-12-10 | 2015-09-29 | Hoffmann La Roche | Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer. |
| US20150174034A1 (en) | 2013-03-13 | 2015-06-25 | Avon Products, Inc. | Tyrosinase inhibitors |
| SI2968284T1 (sl) * | 2013-03-14 | 2021-08-31 | Osteoqc Inc. | Alkil-amin harmin derivati za pospeševanje rasti kosti |
| WO2014151682A1 (en) | 2013-03-14 | 2014-09-25 | Icahn School Of Medicine At Mount Sinai | Pyrimidine compounds as kinase inhibitors |
| GB2519623A (en) | 2013-06-18 | 2015-04-29 | 4Sc Discovery Gmbh | Method of inhibiting DYRK1B |
| CN105555785B (zh) | 2013-06-18 | 2019-03-01 | 4Sc股份公司 | 作为dyrk激酶抑制剂的2,3-二氢苯并呋喃-5-基化合物 |
| US9725463B2 (en) | 2013-06-21 | 2017-08-08 | Lupin Limited | Substituted heterocyclic compounds as CRAC modulators |
| ES2529865B8 (es) | 2013-07-25 | 2016-01-22 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) | USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS |
| SI3057959T1 (en) | 2013-10-17 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | DNA-PK INHIBITORS |
| JP6767875B2 (ja) | 2014-04-08 | 2020-10-14 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法 |
| US20170280720A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016064676A1 (en) | 2014-10-21 | 2016-04-28 | Genzada Pharmaceuticals Llc | Human therapeutic agents |
| ES2985135T3 (es) | 2014-12-18 | 2024-11-04 | Harvard College | Procedimientos para generar células ß derivadas de células madre y usos de las mismas |
| ES2820768T3 (es) | 2015-04-03 | 2021-04-22 | Xoma Technology Ltd | Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1 |
| WO2017008694A1 (zh) | 2015-07-11 | 2017-01-19 | 常州合力电器有限公司 | 直流松土机 |
| US11332716B2 (en) | 2015-07-27 | 2022-05-17 | The Regents Of The University Of California | Methods and compositions for producing pancreatic beta cells |
| AU2016315881B2 (en) | 2015-09-03 | 2019-09-19 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CN105884767B (zh) | 2015-11-24 | 2018-01-19 | 西华大学 | 9‑位取代的吡啶并[3,4‑b]吲哚衍生物及其制备方法和作为SIRT蛋白抑制剂的用途 |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| US10487087B2 (en) | 2015-12-30 | 2019-11-26 | Vanderbilt University | Positive allosteric modulators of the GLP-1 receptor |
| WO2017168245A1 (en) | 2016-04-01 | 2017-10-05 | University Of Limerick | Pharmaceutical compositions and methods for the treatment of diabetes |
| WO2017197151A1 (en) | 2016-05-11 | 2017-11-16 | Emory University | Phosphotidylinositol 3-kinase inhibitors |
| JP6596390B2 (ja) | 2016-06-29 | 2019-10-23 | 株式会社沖データ | 現像剤収容器、現像装置、画像形成装置、及び基板支持構造 |
| WO2018081401A1 (en) | 2016-10-26 | 2018-05-03 | Ichan School Of Medicine At Mount Sinai | Method for increasing cell proliferation in pancreatic beta cells, treatmen t method.and composition |
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| US11279703B2 (en) | 2016-12-01 | 2022-03-22 | Aptose Biosciences Inc. | Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| JP2021510153A (ja) | 2018-01-05 | 2021-04-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 |
| ES3038913T3 (en) | 2018-03-20 | 2025-10-15 | Icahn School Med Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| CA3124353A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CA3124700A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| US20230234935A1 (en) | 2020-06-26 | 2023-07-27 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
-
2019
- 2019-03-20 ES ES19771612T patent/ES3038913T3/es active Active
- 2019-03-20 AU AU2019240065A patent/AU2019240065A1/en not_active Abandoned
- 2019-03-20 CA CA3093340A patent/CA3093340A1/en active Pending
- 2019-03-20 WO PCT/US2019/023206 patent/WO2019183245A1/en not_active Ceased
- 2019-03-20 JP JP2020550798A patent/JP2021518413A/ja active Pending
- 2019-03-20 EP EP19771612.9A patent/EP3768267B1/en active Active
- 2019-03-20 US US16/981,742 patent/US11866427B2/en active Active
- 2019-03-20 CN CN201980032475.XA patent/CN112135613A/zh active Pending
-
2023
- 2023-11-28 US US18/521,801 patent/US12421232B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11866427B2 (en) | 2024-01-09 |
| EP3768267A1 (en) | 2021-01-27 |
| EP3768267B1 (en) | 2025-05-14 |
| CN112135613A (zh) | 2020-12-25 |
| WO2019183245A1 (en) | 2019-09-26 |
| US12421232B2 (en) | 2025-09-23 |
| US20210094950A1 (en) | 2021-04-01 |
| ES3038913T3 (en) | 2025-10-15 |
| JP2021518413A (ja) | 2021-08-02 |
| AU2019240065A1 (en) | 2020-09-24 |
| US20240132494A1 (en) | 2024-04-25 |
| EP3768267A4 (en) | 2022-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12421232B2 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| US10604514B2 (en) | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof | |
| JP5930278B2 (ja) | Mlk阻害剤および使用方法 | |
| US20230234935A1 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| US20220064146A1 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| WO2011158044A2 (en) | Respiratory formulations and compounds for use therein | |
| CN102869358A (zh) | 用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合 | |
| EP3906233B1 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| US10744128B2 (en) | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof | |
| CA3234937A1 (en) | 7h-pyrrolo[2,3-d]pyrimidines and preparation as dyrk1a inhibitors | |
| EP3717475B1 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| HK40062251A (en) | Kinase inhibitor compounds and compositions and methods of use | |
| HK40063467A (en) | Kinase inhibitor compounds and compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20240702 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250314 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250314 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250314 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260313 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260313 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260703 |